Q0239 — Injection, bamlanivimab-xxxx, 700 mg
Q0239 is a HCPCS Level II code for injection, bamlanivimab-xxxx, 700 mg. It belongs to the Temporary Codes section. It was terminated on April 16, 2021 and is not valid on new claims.
This code has been terminated
CMS terminated Q0239 on April 16, 2021. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q0239
- Long descriptor
- Injection, bamlanivimab-xxxx, 700 mg
- Short descriptor
- Bamlanivimab-xxxx
- Added
- November 9, 2020
- Terminated
- April 16, 2021
- BETOS
- O1G
- Pricing indicator
- 54 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Vaccinations.
Codes adjacent to Q0239
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q0239 is not quite right, the correct code is very often within a few positions of it.
- Q0220Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mgterminated
- Q0221Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mgterminated
- Q0222Injection, bebtelovimab, 175 mgterminated
- Q0224Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
- Q0234Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
- Q0235Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
- Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0238Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0240Injection, casirivimab and imdevimab, 600 mgterminated
- Q0243Injection, casirivimab and imdevimab, 2400 mgterminated
- Q0244Injection, casirivimab and imdevimab, 1200 mgterminated
- Q0245Injection, bamlanivimab and etesevimab, 2100 mgterminated
- Q0247Injection, sotrovimab, 500 mgterminated
- Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0477Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
- Q0478Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
Questions about Q0239
What is HCPCS code Q0239?
Q0239 is a HCPCS Level II code for injection, bamlanivimab-xxxx, 700 mg. It sits in the Temporary Codes section.
Does Medicare cover Q0239?
The CMS HCPCS file marks Q0239 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is Q0239 still valid?
No. Q0239 was terminated on April 16, 2021 and should not be used on new claims.